Oncotelic discloses JV IPO target and OT-101 COVID mortality data at BIO2022

Oncotelic Therapeutics, Inc.

JVCo IPO on track for 2023 with anticipated minimum valuation of $200M, range $1-5B.
OT-101 combined with immunotherapies including Keytruda (Merck), Tecentriq (Genentech); in various stages.
OT-101 treatment of high-risk COVID patients reduced mortality from 100% to 50% (p=0.003).
Company presentation at BIO International Convention available on website.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.